Phosphocreatine disodium hydrate

Phosphocreatine (disodium hydrate) 是一种存在于脊椎动物骨骼肌中的有机化合物,可增强抗氧化活性并激活 TAK1 通路以保护心脏,通过 Akt 介导的 Nrf2/HO-1 途径使线粒体功能正常化并减少氧化应激,并通过 ERK 介导的 Nrf-2/HO-1 途径抑制细胞凋亡 (Apoptosis) 和 ROS (Reactive Oxygen Species) 的产生,从而保护肾脏。
产品编号: MS-B46115 纯度: 99.57% CAS No.: 19333-65-4 分子式: C4H10N3O5P.xH2O.2Na
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
100mg
询价
3-5 天
500mg
询价
3-5 天
1g
询价
3-5 天
5g
询价
询价
10g
询价
询价

产品描述

Phosphocreatine (disodium hydrate) 是一种存在于脊椎动物骨骼肌中的有机化合物,可增强抗氧化活性并激活 TAK1 通路以保护心脏,通过 Akt 介导的 Nrf2/HO-1 途径使线粒体功能正常化并减少氧化应激,并通过 ERK 介导的 Nrf-2/HO-1 途径抑制细胞凋亡 (Apoptosis) 和 ROS (Reactive Oxygen Species) 的产生,从而保护肾脏。

生物实验数据

生物活性 Phosphocreatine (disodium hydrate) is an organic compound found in the skeletal muscle of vertebrates that enhances antioxidant activity and activates the TAK1 pathway to protect the heart, normalizes mitochondrial function and reduces oxidative stress via the Akt-mediated Nrf2/HO-1 pathway, and inhibits apoptosis and ROS (Reactive Oxygen Species) production through the ERK-mediated Nrf-2/HO-1 pathway, thereby protecting the kidneys.
IC50 & Target

Human Endogenous Metabolite

 

体外研究
(In Vitro)

非盐形式:
Phosphocreatine (0-1 mM, 24 h) 通过靶向 TAK1 揭示了抗氧化、抗凋亡和抗坏死性凋亡的作用,以保护 H9c2 细胞免受 DOX (Doxorubicin) (HY-15142A) 诱导的心肌细胞损伤。
Phosphocreatine (0-1 mM, 24 h) 通过增加抗氧化活性来缓解氧化应激,随后将 TAK1 的表达水平恢复到基线水平,并减少 DOX 诱导的心肌损伤中的细胞凋亡和程序性死亡。
Phosphocreatine (5-20 mM, 24 h) 可减轻 MGO (Methylglyoxal) (MS-L54006) 诱导的 PC12 细胞损伤和抑制 PC-12 细胞凋亡。
Phosphocreatine (5-20 mM, 24 h) 可防止 MGO (Methylglyoxal) 诱导损伤的 PC-12 细胞线粒体膜通透性丧失。
Phosphocreatine (5-20 mM, 2 h) 对 PC-12 细胞的神经保护作用依赖于通过 Akt 介导的 Nrf2/HO- 1途径使线粒体功能正常化和减少氧化应激。
Phosphocreatine (5-40 mM, 24 h) 在不同浓度下可能有助于保护 NRK-52E 细胞免受 MGO 诱导的肾损伤。
Phosphocreatine (10-40 mM, 4 h) 抑制肾脏氧化应激代谢物。

Apoptosis Analysis

Cell Line: PC-12, NRK-52E cells
Concentration: 5, 10, 20, 40 mM
Incubation Time: 2 h
Result: Significantly suppressed the enhanced early apoptosis in PC-12 cells in a dose-dependent manner.
Increased the expression of Bcl-2, procaspase-3 and procaspase-9 in NRK-52E cells.
Decreased the expression of Bax and cleaved caspase-3 in NRK-52E cells.
Suppressed karyorrhexis and karyopyknosis in NRK-52E cells.
Decreased the apoptotic rate compared with MGO-treated cells in NRK-52E cells.
Prevented the losing of MMP (mitochondrial membrane potential) in NRK-52E cells.

Cell Viability Assay

Cell Line: PC-12, NRK-52E cells
Concentration: 0, 5, 10, 20, 40 mM
Incubation Time: 24 h
Result: Was not toxic to PC-12 cells under the treatment conditions.
Significantly increased PC-12 cell viability at the concentrations of 5, 10 and 20 mM compared with MGO (Methylglyoxal) (MS-L54006) groups.
Contributed to protection of the NRK-52E cells against MGO-induced kidney injury.

Western Blot Analysis

Cell Line: PC-12, NRK-52E cells
Concentration: 20, 40 mM
Incubation Time: 24 h
Result: Increased the expression levels of Akt, Nrf2 (nuclear factor (erythroid-derived-2)-like 2 (Nrf2)) and HO-1 (Hemeoxygenase-1) in PC12 cells.
Increased the expression of nuclear Nrf2 levels, and decreased Nrf2 level in PC12 cells cytoplasm.
Increased the expression of p-Akt, HO-1 and Nrf2 with compared with pre-treatment for 2 h with LY294002 (a PI3K inhibitor) in PC12 cells.
Significantly increased Bcl-2 and procaspase-9 levels and decreased Bax, cleaved caspase-9 and cleaved caspase-3 C level in NRK-52E cells.
Decreased the expression of p-ERK and increased the Nrf2 and HO-1 expressions in NRK-52E cells.
体内研究
(In Vivo)

非盐形式:
Phosphocreatine (200 mg/kg, i.p., 每隔一天一次, 7 周) 不仅减轻了氧化应激和心肌细胞凋亡,而且挽救了 DOX 诱导的大鼠心脏毒性中的心肌坏死。
Phosphocreatine (20-40 mg/kg, i.v., 每天, 6 周) 对 SD (Sprague-Dawley) 大鼠的肾组织具有保护作用,可预防糖尿病肾病。

Animal Model: Male Sprague Dawley (SD) rats, i.p., normal saline, 3 times; i.p., DOX 2 mg/kg, 7 times; i.p., normal saline, 3 times
Dosage: 200 mg/kg
Administration: i.p., once every other day, 7 weeks
Result: Improved the heart function abnormality.
Lowered myocardial apoptosis.
Recovered the expression of Nrf2, SOD, FoxO3a and diminished C-Casp3, Bax/Bcl2 in the myocardial tissue of rats.
Markedly improved myocardial necroptosis, as indicated by decreasing expression of RIP3 and CaMKII.
Increased expression level of TAK1.
Animal Model: Male Sprague Dawley (SD) rats, i.p., 70 mg/kg (STZ(Streptozotocin) (MS-Q80520)), daily, 6 weeks
Dosage: 20, 40 mg/kg
Administration: i.p., daily, 6 weeks
Result: Reduced hyperglycemia compared with STZ (Streptozotocin) (MS-Q80520) -treated rats.
Increased the weight of rats gradually compared with STZ (Streptozotocin) (MS-Q80520) group.
Decreased kidney weight index (kidney weight/body weight).
Decreased MDA level and increased of GSH and SOD levels compared with STZ group.
Decreased the apoptotic rate compared with MGO-treated groups.
性状 固体
颜色 White to off-white

化学信息

分子式 C4H10N3O5P.xH2O.2Na
CAS No. 19333-65-4

储存&溶解度

溶解度信息
DMSO: Slightly soluble
H2O: 250 mg/mL (915.45 mM)
体内实验配方
PBS: 100 mg/mL (366.18 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础